| The International Neuroblastoma Risk Group (INRG) classification system: an INRG task force report SL Cohn, ADJ Pearson, WB London, T Monclair, PF Ambros, GM Brodeur, ... Journal of clinical oncology 27 (2), 289-297, 2009 | 2104 | 2009 |
| Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma AL Yu, AL Gilman, MF Ozkaynak, WB London, SG Kreissman, HX Chen, ... New England Journal of Medicine 363 (14), 1324-1334, 2010 | 1948 | 2010 |
| The international neuroblastoma risk group (INRG) staging system: an INRG task force report T Monclair, GM Brodeur, PF Ambros, HJ Brisse, G Cecchetto, K Holmes, ... Journal of clinical oncology 27 (2), 298-303, 2009 | 1240 | 2009 |
| The genetic landscape of high-risk neuroblastoma TJ Pugh, O Morozova, EF Attiyeh, S Asgharzadeh, JS Wei, D Auclair, ... Nature genetics 45 (3), 279-284, 2013 | 1223 | 2013 |
| Activating mutations in ALK provide a therapeutic target in neuroblastoma RE George, T Sanda, M Hanna, S Fröhling, WL Ii, J Zhang, Y Ahn, ... Nature 455 (7215), 975-978, 2008 | 1026 | 2008 |
| Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13-cis-Retinoic Acid: A … KK Matthay, CP Reynolds, RC Seeger, H Shimada, ES Adkins, ... Journal of clinical oncology 27 (7), 1007-1013, 2009 | 998 | 2009 |
| Advances in risk classification and treatment strategies for neuroblastoma NR Pinto, MA Applebaum, SL Volchenboum, KK Matthay, WB London, ... Journal of clinical oncology 33 (27), 3008-3017, 2015 | 855 | 2015 |
| Chromosome 1p and 11q deletions and outcome in neuroblastoma EF Attiyeh, WB London, YP Mossé, Q Wang, C Winter, D Khazi, ... New England Journal of Medicine 353 (21), 2243-2253, 2005 | 741 | 2005 |
| Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group WB London, RP Castleberry, KK Matthay, AT Look, RC Seeger, ... Journal of clinical oncology 23 (27), 6459-6465, 2005 | 695 | 2005 |
| Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease CK Tebbi, WB London, D Friedman, D Villaluna, PA De Alarcon, ... Journal of Clinical Oncology 25 (5), 493-500, 2007 | 538 | 2007 |
| Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project HJ Brisse, MB McCarville, C Granata, KB Krug, SL Wootton-Gorges, ... Radiology 261 (1), 243-257, 2011 | 474 | 2011 |
| A modified γ-retrovirus vector for X-linked severe combined immunodeficiency S Hacein-Bey-Abina, SY Pai, HB Gaspar, M Armant, CC Berry, S Blanche, ... New England Journal of Medicine 371 (15), 1407-1417, 2014 | 465 | 2014 |
| International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee PF Ambros, IM Ambros, GM Brodeur, M Haber, J Khan, A Nakagawara, ... British journal of cancer 100 (9), 1471-1482, 2009 | 462 | 2009 |
| Copy number variation at 1q21. 1 associated with neuroblastoma SJ Diskin, C Hou, JT Glessner, EF Attiyeh, M Laudenslager, K Bosse, ... Nature 459 (7249), 987-991, 2009 | 447 | 2009 |
| ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma SC Bresler, DA Weiser, PJ Huwe, JH Park, K Krytska, H Ryles, ... Cancer cell 26 (5), 682-694, 2014 | 418 | 2014 |
| Clinicopathologic features and long-term outcomes of NUT midline carcinoma DE Bauer, CM Mitchell, KM Strait, CS Lathan, EB Stelow, SC Lüer, ... Clinical Cancer Research 18 (20), 5773-5779, 2012 | 413 | 2012 |
| Children's Oncology Group's 2013 blueprint for research: neuroblastoma JR Park, R Bagatell, WB London, JM Maris, SL Cohn, KM Mattay, ... Pediatric blood & cancer 60 (6), 985-993, 2013 | 410 | 2013 |
| Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study D Billmire, C Vinocur, F Rescorla, B Cushing, M Schlatter, M Davis, ... Journal of pediatric surgery 39 (3), 424-429, 2004 | 360 | 2004 |
| Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease EB Esrick, LE Lehmann, A Biffi, M Achebe, C Brendel, MF Ciuculescu, ... New England Journal of Medicine 384 (3), 205-215, 2021 | 357 | 2021 |
| Outcome after reduced chemotherapy for intermediate-risk neuroblastoma DL Baker, ML Schmidt, SL Cohn, JM Maris, WB London, A Buxton, ... New England Journal of Medicine 363 (14), 1313-1323, 2010 | 352 | 2010 |
